What is Biosyntia?
Founded in 2012 by Hans Genee, Andreas Lausten, and Professor Morten Sommer, Biosyntia specializes in developing bio-based manufacturing processes through advanced strain engineering and fermentation. The company leverages its proprietary Biosynthetic Selections technology to dramatically reduce the risk, cost, and time associated with developing fermentation processes. This innovative approach has enabled Biosyntia to achieve unprecedented speed and efficiency in its development cycles, earning it over 15 recognition awards, including being named one of Europe's most innovative SMEs in 2016. Biosyntia's core mission is to revolutionize industrial biotechnology by creating more sustainable and cost-effective manufacturing solutions.
How much funding has Biosyntia raised?
Biosyntia has raised a total of $13.6M across 2 funding rounds:
Angel/Seed
$1.9M
Other Financing Round
$11.7M
Angel/Seed (2015): $1.9M with participation from Novo A/S
Other Financing Round (2022): $11.7M led by Sofinnova Partners, European Circular Bioeconomy Fund, and Novo Seeds
Key Investors in Biosyntia
Novo A/S
Novo Holdings is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation, focusing on investments within the life sciences sector.
European Circular Bioeconomy Fund
The European Circular Bioeconomy Fund (ECBF) is a venture capital firm dedicated to investing in pioneering companies within the regenerative economy, aiming to foster sustainable bioeconomy solutions.
Novo Seeds
Novo Seeds is an investment entity that supports early-stage companies, likely focusing on innovative ventures within the life sciences and biotechnology fields.
What's next for Biosyntia?
With the recent infusion of major strategic capital, Biosyntia is poised to further enhance its technological capabilities and scale its operations. The company's focus on accelerating the development of fermentation processes suggests a strategic push towards commercialization and broader market adoption. Future investments are likely to be directed towards expanding its R&D infrastructure, forging strategic partnerships, and scaling production capacity to meet growing industry demand for bio-based alternatives. The company's trajectory indicates a strong emphasis on innovation and sustainable manufacturing, positioning it as a key player in the future of industrial biotechnology.
See full Biosyntia company page
